tbuckley/cabot-search huggingface dataset:
260P Antitumor activity of trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (mBC) and brain metastases (BMs) from DAISY trial
Authors: N. Epaillard, A. Lusque, B. Pistilli, F. André, T. Bachelot, J-Y. Pierga, A. Ducoulombier, C. Jouannaud, F. Viret, L. Salabert, A.C. Johnson, E. Deluche, X. Durando, T. Petit, T. Filleron, C. Mahier Ait Oukhatar, V.C. Dieras, M.F. Mosele
Journal: Annals of Oncology (2022)
886TiP Recombinant human adenovirus type 5 combined with anti-PD-1 monoclonal antibody in the treatment of patients with advanced melanoma with previous immunotherapy failure: A single-site, single-arm, prospective study
Authors: J. Lin, B. Lan, L. Chen, L. Chen, Y. Huang, M. You, J. Liu, J. Xiong, H. Zhang, Y. Chen
Journal: Annals of Oncology (2022)
559P Neratinib in HER2-mutant, recurrent/metastatic cervical cancer (R/M CC): Updated findings from the phase 2 SUMMIT basket trial
Authors: C.F. Friedman, A.A. D'Souza, A.V. Tinker, E. Corral, V. Gambardella, J.W. Goldman, S. Loi, M. Melisko, A. Oaknin, I. Spanggaard, A.M. VanderWalde, A.L. Frazier, B. Zhang, L.D. Eli, D.B. Solit
Journal: Annals of Oncology (2022)
550P Immunoprofiling of mismatch repair-deficient (MMRd) endometrial cancer (EC) patients (pts): Immune checkpoint inhibitor (ICI)-responders (R) versus non-responders (NR)
Authors: J.F. Grau Béjar, E. Yaniz Galende, C. Genestie, J-Y. Scoazec, E. Edmond, A. Le Formal, F. Blanc-Durand, J. Michels, M. Kfoury, P. Morice, P. Pautier, E. Colomba, A. Leary
Journal: Annals of Oncology (2022)
TCT-46 Pre-Hospital Crushed Versus Integral Prasugrel Loading Dose in Patients Presenting With Anterior ST-Segment Elevation Myocardial Infarction—A COMPARE CRUSH Subanalysis
Authors: Rosanne Vogel, Jeroen Wilschut, Ronak Delewi, Miguel Lemmert, Roberto Diletti, Rutger Nuis, Valeria Paradies, Dimitrios Alexopoulos, Felix Zijlstra, Gilles Montalescot, Dominick Angiolillo, Mitchell Krucoff, Nicolas van Mieghem, Pieter Smits, Georgios Vlachojannis
Journal: Journal of the American College of Cardiology (2022)
226P Exploring the impact of first-line therapies on the metastatic behavior of luminal-like metastatic breast cancer (mBC)
Authors: R. Mazzeo, B. Pastò, D. Basile, L. Bortot, L. Cucciniello, A. Dri, C. Noto, S. Buriolla, L. Palmero, A. Membrino, M. Bonotto, C. Lisanti, S. Russo, A.M.M. Minisini, G. Fasola, L. Gerratana, F. Puglisi
Journal: Annals of Oncology (2022)
329P Duration of adjuvant therapy in stage III colon cancer: A real world multi-institutional US-based experience
Authors: D. Walden, F-S. Ou, J. Larson, None S. Kang, A. Liu, D. Huff, C. Griswold, B. Ueberroth, P. Bhamini, A. Draper, B. Grieb, K.K. Ciombor, P. Raman, M.B. Sonbol, M. Borad, T. Bekaii-Saab, C. Wu, D. Ahn
Journal: Annals of Oncology (2022)
534P A pilot study of neoadjuvant olaparib for patients with HRD-positive advanced ovarian cancer
Authors: K. Harano, T. Nakao, S. Nishio, T. Katsuda, K. Tasaki, K. Takehara, T. Yokoyama, H. Furuya, K. Hongo, M. Asano, T. Ikeno, M. Wakabayashi, A. Sato, H. Tanabe, T. Taki, R. Watanabe, G. Ishii, T. Mukohara
Journal: Annals of Oncology (2022)
531P Maintenance olaparib monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) without a germline BRCA1/BRCA2 mutation (non-gBRCAm): Final overall survival (OS) results from the OPINION trial
Authors: A.M. Poveda Velasco, S. Lheureux, N. Colombo, D. Cibula, M. Elstrand, J. Weberpals, M. Bjurberg, A. Oaknin, M. Sikorska, A.J. Gonzalez Martin, R. Madry, M.J. Rubio Perez, J.A. Ledermann, O. Ozgoren, A. Barnicle, H. Marshall, Z. Bashir, E. Skof
Journal: Annals of Oncology (2022)
496MO Final overall survival results from the NICE-NEC trial (GETNE-T1913): A phase II study of nivolumab and platinum-doublet chemotherapy (CT) in untreated advanced G3 neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or unknown (UK) origin
Authors: M.C. Riesco Martinez, J. Capdevila Castillon, V. Alonso, P. Jimenez-Fonseca, A. Teule, E. Grande, I. Sevilla, M. Benavent, T. Alonso-Gordoa, A. Custodio, B. Antón Pascual, J. Hernando, E. Polo, O.A. Castillo Trujillo, R. Garcia-Carbonero
Journal: Annals of Oncology (2022)
241P Genomic analysis of plasma cell-free DNA in patients with heavily pretreated HER-2+ metastatic breast cancer (MBC)
Authors: K. Lee, J. Lee, J. Choi, S.H. Sim, J.E. Kim, M.H. Kim, Y.H. Park, J.H. Kim, S. Koh, K.H. Park, M.J. Kang, M.S. Ahn, K-E. Lee, H.J. Kim, H. Ahn, H.J. Kim, K.U. Park, I.H. Park
Journal: Annals of Oncology (2022)
125P Assessing the accuracy of multiple prognostic scores for immune checkpoint inhibitors (ICI) in patients with advanced solid tumors
Authors: J. Garcia-Corbacho, A. Indacochea, A. Gonzalez, I. Victoria Ruiz, D. Moreno Fernández, D.S. Pesantez Coronel, L. Angelats, A. Modrego, E. Sanfeliu Torres, O. Castillo, P. Blasco, L. Mezquita, N. Vinolas Segarra, M. Nogue Aliguer, B. Adamo, N. Baste Rotllan, T. Sauri Nadal, M. Juan, A. Prat, F. Schettini
Journal: Annals of Oncology (2022)
520MO Safety and efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic cervical cancer (R/M Cx Ca) in checkmate 358
Authors: A. Oaknin, K.N. Moore, T. Meyer, J.L. González, L. Devriese, A. Amin, C.D. Lao, V. Boni, W.H. Sharfman, J.C. Park, M. Tahara, S.L. Topalian, M.E. Magallanes Maciel, A. Molina Alavez, A. Khan, C. Copigneaux, M. Lee, C. Garnett-Benson, X. Wang, R.W. Naumann
Journal: Annals of Oncology (2022)
216MO A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) vs weekly paclitaxel (P) as first- or second-line treatment in patients (pts) with ER+/HER2- metastatic breast cancer (MBC): The METEORA-II trial (IBCSG 54-16)
Authors: E. Munzone, M.M. Regan, S. Cinieri, E. Montagna, L. Orlando, R. Shi, E. Campadelli, L. Gianni, U.F.F. De Giorgi, C. Bengala, D. Generali, E. Collova, F. Puglisi, E. Cretella, C. Zamagni, C. Chini, A. Goldhirsch, M.A. Colleoni
Journal: Annals of Oncology (2022)
420P The role of HIPEC in the management of gastrointestinal and biliary tract malignancies: Systematic review and meta-analysis of randomized data
Authors: P. Filis, A. Kanellopoulou, A. Gogadis, N. Filis, K.V. Kamposioras, F. Kapoulitsa, D. Mauri
Journal: Annals of Oncology (2022)
236P Subgroup analysis by disease history and prior treatments of patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1)
Authors: J. Cortés, S-A. Im, H. Iwata, E.P. Hamilton, S.A. Hurvitz, A. Egorov, J. Cathcart, Y. Liu, E. Bako, G. Curigliano
Journal: Annals of Oncology (2022)
521MO Efficacy of pembrolizumab monotherapy (PM) for advanced clear cell gynaecological cancer (CCGC): Phase II PEACOCC trial
Authors: R. Kristeleit, A.R. Clamp, C. Gourley, R. Roux, M. Hall, M-J. Devlin, R. Nirsimloo, V. Kounnis, L. Hughes, N. Counsell, L. Farrelly, R. Miller
Journal: Annals of Oncology (2022)
CN26 Nurses caring for patients at the end of life report affected psychosocial work environment when relocated during the COVID-19 pandemic: A cross-sectional study
Authors: C. Olsson, M. Dahlen Granrud, M. Tillfors, C. Bååth, V. Abrahamsen Grøndahl, A.K. Helgesen, I. Henoch, C. Melin-Johansson, J. Österlind, M. Larsson
Journal: Annals of Oncology (2022)
CN37 Patient and public involvement in research: Reflections and experiences of doctoral cancer nurse researchers in Europe
Authors: M.A. Tanay, C. Díez de los Ríos de la Serna, V. Boland, A.M.D.S. Lopes, M. Dornan, K. Wingfield, G. Yildiz, D. Chircop, G. Suchodolska, B. Kurt, S. Colomer-Lahiguera
Journal: Annals of Oncology (2022)
518O Overall survival results from ARIEL4: A phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation
Authors: A.M. Oza, A.S. Lisyanskaya, A.A. Fedenko, A.C. de Melo, Y. Shparik, I. Bondarenko, N. Colombo, D. Lorusso, D. Cibula, R.L. Póka, A. Oaknin, T. Safra, B. Maćkowiak-Matejczyk, L. Ma, D. Thomas, K.K. Lin, K. McLachlan, S. Goble, R. Kristeleit
Journal: Annals of Oncology (2022)
220P Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALD
Authors: P.G. Aftimos, J. Cortés, F.C. Bidard, None V. Kaklamani, A. Bardia, P. Neven, G. Streich, A. Montero, F. Forget, M.A. Mouret Reynier, J. Sohn, D. Taylor, K. Harnden, H. Khong, J. Kocsis, F. Dalenc, P. Dillon, G. Tonini, K.J. Grzegorzewski, J. Lu
Journal: Annals of Oncology (2022)
225P MET-enriched circulating tumor cells and cell-free DNA concentration as significant independent predictors for progression in HR-positive HER2-negative metastatic breast cancer
Authors: J. Park, E.S. Chang, J-Y. Kim, C. Chelakkot, M. Sung, J-Y. Song, K. Jung, N.Y. Kim, Y.H. Park, Y.K. Shin, Y-L. Choi
Journal: Annals of Oncology (2022)
530P PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety
Authors: A.J. Gonzalez Martin, B. Pothuri, I.B. Vergote, W. Graybill, M.R. Mirza, C. Mccormick, D. Lorusso, G. Freyer, F. Backes, K.H. Baumann, A. Redondo Sanchez, R.G. Moore, C. Vulsteke, R.E. O'Cearbhaill, I. Malinowska, L. Shtessel, N. Compton, B.J. Monk
Journal: Annals of Oncology (2022)
368P Characteristics and survival of metastatic colorectal cancer patients receiving local treatment with deficient mismatch repair versus proficient mismatch repair
Authors: J. Roodhart, K. Zwart, C.J.A. Punt, E. Wensink, K. Bolhuis, M.M. Laclé, W. van Grevenstein, J. Hagendoorn, I.H.J.T. de Hingh, M. Koopman, G. Vink, F. van der Baan
Journal: Annals of Oncology (2022)
770P Comprehensive immune profiling of primary tumors, lymph nodes, and peripheral blood after treatment with nivolumab and BMS 986205 in head and neck squamous cell carcinoma (HNSCC)
Authors: L. Harshyne, A. Linnenbach, M. Mahoney, A. South, U. Martinez-Outschoorn, J.M. Curry, D. Cognetti, J.M. Johnson, M. Tuluc, A. Argiris, A. Luginbuhl
Journal: Annals of Oncology (2022)
121P Spectrum of druggable gene fusions in microsatellite-unstable colorectal tumors
Authors: E. Imyanitov, A. Anuskina, A.G. Iyevleva, N.V. Mitiushkina, R. Mulkidzhan, E. Preobrazhenskaya, A. Romanko, E. Saitova, V. Tiurin
Journal: Annals of Oncology (2022)
431P Neoadjuvant treatment with regorafenib and capecitabine combined with radiotherapy in locally advanced rectal cancer: A multicenter phase Ib trial (RECAP) SAKK 41/16
Authors: S. Bastian, M. Joerger, D. Baertschi, L. Holer, M. Guckenberger, W. Jochum, D. Koeberle, A.R. Siebenhüner, M.D. Berger, R.C. Winterhalder, C.R. Largiadèr, M. Löffler-Baumann, K. Mosna- Firlejczyk, A. Wicki, A. Fischer Maranta, R.A.F. von Moos
Journal: Annals of Oncology (2022)
891P Naxitamab treatment for relapsed or refractory high-risk neuroblastoma: Outcomes from the first prespecified analyses of the Pivotal 201 Trial
Authors: J. Mora, M. Bear, G. Chan, D.A. Morgenstern, K. Nysom, K. Tornøe, P.S. Sørensen, B. Kushner
Journal: Annals of Oncology (2022)
429P Management of localized anal cancer and prognostic factors in the elderly: Results of the French multicenter cohort FFCD – ANABASE
Authors: C. Gouriou, C. Lemanski, P. Pommier, K. Le Malicot, A. Saint, E. Rivin del Campo, C. Evin, L. Quero, P. Regnault De La Motte, N. Baba Hamed, R. Philippe, G. Crehange, D. Tougeron, E. Menager-Tabourel, O. Diaz, M. Hummelsberger, A. de la Rochefordière, F. Drouet, V. Vendrely, A. Lievre
Journal: Annals of Oncology (2022)
1027P 1-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer
Authors: C. Verschraegen, Z.G. Andric, T-E. Ciuleanu, F.V. Moiseenko, T. Makharadze, S. Shevnia, A. Oleksiienko, E. Yanez Riuz, S.H. Kim, K.Y. Ahn, T.H. Park, S. Park, E.H. Baek, S. Kwon, H.A. Ju, S.J. Lee, S.H. Kim, H.A. Kim, E.K. Lee, Y. Ohe
Journal: Annals of Oncology (2022)
493TiP A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER-3 antibody) in patients with advanced HER3-positive solid tumours
Authors: J.S. de Bono, S. Lord, C. Yap, E.K. Rowinsky, N.A. Gandhi, D. Thakkar, P.J. Ingram, N. Padmanabhan, K. Chandran, A. Paschalis, L. McGuigan, P. Neal, D. Paisley, H.S. Walter, F. Kelly, J. Craigan, N.B. Westwood, G. Halbert, J.D. Boyd-Kirkup, S.E.R. Halford
Journal: Annals of Oncology (2022)
309P Patients with relapsed adult medulloblastoma (MB) treated by the GEINO (Spanish cooperative group for research in neuro-oncology) group oncologists: Natural history and patterns of care
Authors: M. Vieito Villar, R. Luque Caro, M.C. Martín Soberon, S. Del Barco Berron, E. Pineda, M.Á. Vaz Salgado, M.T. Tuñon, A. Herrero Ibañez, T. Quintanar Verduguez, J. Diaz Santos, R. Girones Sarrio
Journal: Annals of Oncology (2022)
941P PET-derived parameters for response assessment in neoadjuvant atezolizumab: A secondary analysis of PRINCEPS phase II trial
Authors: F.G. Dall'Olio, L. Mabille, C.A. Garcia, J. Adam, M.R. Ghigna, N. Cozic, C. Caramella, N. Chaput-Gras, D. Planchard, L. Mezquita, J. Remon Masip, P. Lavaud, C. Naltet, A. Gazzah, V. Thomas De Montpreville, O. Mercier, F. Barlesi, B. Besse
Journal: Annals of Oncology (2022)
156P Low CD2 expression in sentinel lymph nodes of early breast cancer patients is associated with postoperative tumor recurrence or metastasis
Authors: S.Y. Kang, T-H. Kim, M.S. Ahn, Y.W. Choi, M. Kwon, H.W. Lee, J-H. Choi, J-H. Kim
Journal: Annals of Oncology (2022)
555P TQB2450 injection combined with anlotinib hydrochloride capsule in the treatment of advanced, recurrent or metastatic endometrial cancer: A multicohort, open label, multicenter phase II clinical trial - The TQB2450-II-08 trial
Authors: X. Wu, S. Liang, X. Chen, J. Hou, K. Wang, D. Wang, R. An, A. Zang, X. Li, B. Zhang, P. Qu, W. Duan, G. Yu, D. Wang, D. Yan, J. Wang, D. Yao, S. Wang, W. Zhao, H. Lou
Journal: Annals of Oncology (2022)
1029P Two-year follow-up from KN046 in combination with platinum doublet chemotherapy as first-line (1L) treatment for NSCLC: An open-label, multi-center phase II trial
Authors: Y. Zhao, G. Chen, X. Li, J. Wu, B. Chang, S. Hu, S. Yang, Y. Liu, N. Wang, Y. Huang, L. Zhang
Journal: Annals of Oncology (2022)
1067P Discovery of a new CD4+ T cell cluster that correlates PD-1 blockade efficacy
Authors: H. Kagamu, S. Yamasaki, K. Horimoto, S. Kitano, O. Yamaguchi, A. Mouri, A. Shiono, Y. Miura, K. Hashimoto, H. Imai, K. Kaira, K. Kobayashi
Journal: Annals of Oncology (2022)
CN1 Patient-reported symptom monitoring improves health-related quality of life in lung cancer patients: The SYMPRO-Lung trial
Authors: N.E. Billingy, V. Tromp, A. Becker, R. Hoek, N. Aaronson, H-J. Bogaard, J. Hugtenburg, B. Onwuteaka-Philipsen, L.V. Van De Poll-Franse, J. Belderbos, C. Van den Hurk, I. Walraven
Journal: Annals of Oncology (2022)
301P Hypofractionated radiotherapy for the treatment of newly diagnosed high-grade gliomas in younger and good performance status patients during COVID-19 pandemic
Authors: A.C. Valente, C. Lopes Almeida, M.J. Costa, I.C. Nogueira Costa, J.S. Reis, M.C.B. Freitas, C.M. Teixeira, M.V. Gonçalves, A.C. Fernandes, A.S.A. Costa, C.L.B. Caeiro, L. Osório, I.M. Augusto, M. Barbosa
Journal: Annals of Oncology (2022)
256P Difference of immunological status and response to immune checkpoint inhibitor between recurrent and de novo stage IV HER2-negative breast cancer in NEWBEAT trial (WJOG9917BTR)
Authors: Y. Ozaki, S. Kitano, M. Yamashita, D. Ikarashi, J. Tsurutani, T. Iwasa, M. Takahashi, T. Mukohara, N. Masuda, M. Futamura, H. Minami, K. Matsumoto, Y. Tanabe Hashimoto, H. Kawabata, K. Yoshimura, T. Takano
Journal: Annals of Oncology (2022)
709P Real-world systemic treatment patterns of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma (HCC)
Authors: A.G. Singal, K. Ozgurdal, X. Fan, Z. Vassilev, C-C. Chen, J.K. Multani, Z. Zhou, J. He, F. Pisa
Journal: Annals of Oncology (2022)
406P Real-world evidence of efficacy and safety in first-line cetuximab treatment of RAS wild-type metastatic colorectal cancer: A multicenter retrospective study in Taiwan
Authors: C-C. Chen, S-C. Chang, Y-Y. Chang, B-W. Lin, H-H. Chen, Y-Y. Hsieh, H-C. Hsu, M-C. Hsieh, F-C. Kuan, C.C. Wu, W-C. Lu, Y-L. Su, Y-H. Liang, C. Chen, S-Y. Huang, C.Y. Wang
Journal: Annals of Oncology (2022)
345P The prognostic value of pre-treatment circulating biomarkers of systemic inflammation (CRP, neutrophil-to-lymphocyte ratio, IL-6, and YKL-40) in vulnerable older patients with metastatic colorectal cancer: The randomized NORDIC9-study
Authors: G. Liposits, H. Skuladottir, J. Ryg, S.B. Winther, S. Möller, E. Hofsli, C-H. Shah, L. Poulsen Oestergaard, A. Berglund, C. Qvortrup, P.J. Osterlund, J.S. Johansen, B. Glimelius, H. Sorbye, P. Pfeiffer
Journal: Annals of Oncology (2022)
651O Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study
Authors: M.R. Dzienis, J.E. Cundom, C.S. Fuentes, A.R. Hansen, M.J. Nordlinger, A.V. Pastor, P. Oppelt, A. Neki, R.W. Gregg, I.P.F. Lima, F.A. Franke, G.F. da Cunha Junior, J.E. Tseng, T. Loree, A.J. Joshi, J.S. Mccarthy, N. Naicker, Y. Sidi, B. Gumuscu, G. De Castro
Journal: Annals of Oncology (2022)
148P Serum metabolomics based risk assessment of disease recurrence in elderly patients with early breast cancer (eBC)
Authors: E. Risi, A. Vignoli, C. Lisanti, C. Biagioni, A. Paderi, S. Cappadona Sciammetta, F. Del Monte, E. Moretti, G. Sanna, L. Livraghi, L. Malorni, M. Benelli, F. Puglisi, C. Luchinat, L. Tenori, L. Biganzoli
Journal: Annals of Oncology (2022)
140MO HER2DX genomic test in HER2-positive/hormone receptor-positive (HER2+/HR+) breast cancer (BC) treated with neoadjuvant trastuzumab (T) and pertuzumab (P): A correlative analysis from the PerELISA trial
Authors: V. Guarneri, M.V. Dieci, G. Griguolo, L. Pare Brunet, M. Marin, F. Miglietta, M. Bottosso, C.A. Giorgi, P. Blasco, O. Castillo, P. Galván, P. Jares, J.A. Puig-butille, A. Vivancos, P. Villagrasa Gonzalez, J. Parker, C.M. Perou, P.F. Conte, A. Prat
Journal: Annals of Oncology (2022)
262P Niraparib plus aromatase inhibitors (AI) for germinal mutated BRCA1/2 (gBRCAm) or homologous recombination-deficient (HRd), hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): LUZERN interim analysis
Authors: I. Pimentel, L. Lema Roso, M. Ramos Vazquez, J.Á. García Saenz, P. Palacios-Ozores, J. De la Haba Rodriguez, S. Blanch, A. Prat, J.E. Ales Martínez, E. Alba Conejo, J. Balmaña, J.M. Perez Garcia, M. Sampayo-Cordero, A. Malfettone, J. Cortés, A. Llombart Cussac
Journal: Annals of Oncology (2022)
323P Five-year efficacy and safety in a randomized phase III trial investigating duration of adjuvant oxaliplatin-based therapy (3- vs. 6-months) for patients with high-risk stage II colon cancer: ACHIEVE-2 trial
Authors: A. Makiyama, K. Yamazaki, M. Shiozawa, D. Manaka, M. Kotaka, Y. Sakamoto, A. Shiomi, Y. Munemoto, T. Rikiyama, M. Fukunaga, U. Takashi, K. Shitara, H. Shinkai, N. Tanida, E. Oki, T. Misumi, E. Sunami, A. Ohtsu, Y. Maehara, T. Yoshino
Journal: Annals of Oncology (2022)
TCT-168 Clinical Outcomes of Biodegradable Polymer-Coated Ultrathin Strut Sirolimus-Eluting Stents in a Real-World Patient Population With High-Risk Subgroups: Three-Year Results
Authors: Dr. Ramesh Babu Pothineni, Vikrant Vijan, Sai Sudhakar Mantravadi
Journal: Journal of the American College of Cardiology (2022)
747P Phase I study of SAR444245 (SAR’245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors
Authors: G.S. Falchook, S. Fu, C. Lemech, M.A. Mckean, A.A. Azad, H.K. Gan, D. Sommerhalder, J.S. Wang, T.J.Y. Tan, C.E. Chee, M. Barve, J. Moser, J. Mooney, N. Acuff, R. Wang, N. Marina, G. Abbadessa, M. Streit, S. Ramusovic, T. Meniawy
Journal: Annals of Oncology (2022)
373P The role of concomitant RAS and BRAF mutations in influencing clinical outcome during BRAF-targeted treatment for metastatic colorectal cancer
Authors: A. Pretta, P. Ziranu, D. Spanu, E. Lai, M. Dettori, C. Manai, F. Balconi, R. Intini, None S. Murgia, A.G. Leone, M. Pozzari, C. Rasola, F. Bardanzellu, G. Maddalena, V. Pusceddu, M. Puzzoni, F. Pietrantonio, F. Bergamo, S. Lonardi, M. Scartozzi
Journal: Annals of Oncology (2022)
362P Phase Ia study to evaluate GDC-6036 monotherapy in patients with colorectal cancer (CRC) with KRAS G12C mutation
Authors: J. Desai, S-W. Han, M.D. Forster, T.W. Kim, G. Alonso Casal, E. Shacham Shmueli, S.E. Bowyer, M.J. De Miguel, A. Falcon Gonzalez, R.H. Jones, M.G. Krebs, W.H. Miller, L. Paz-Ares, P. Lorusso, A. Sacher, N. Dharia, M.T. Lin, J.L. Schutzman, Z. Shi, M. Patel
Journal: Annals of Oncology (2022)
139MO Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial
Authors: M. Rediti, D. Venet, A. Joaquin Garcia, D. Agbor-tarh, M. Maetens, D. Vincent, S. Majjaj, S. El-Abed, M.C. Liu, S. Di Cosimo, M. Piccart, L. Pusztai, S. Loi, R.F. Salgado, G. Viale, F. Rothé, C. Sotiriou
Journal: Annals of Oncology (2022)
114P Clinical interchangeability of programmed cell death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays for the treatment of first-line (1L) non-small cell lung cancer (NSCLC) with cemiplimab
Authors: K.M. Kerr, J. Perez, K. McGuire, B. Baker, F. Fang, J. Li, G. Wlasiuk, S. Li, B. Gao, J-F. Pouliot, F. Seebach, I. Lowy, G. Gullo, P. Rietschel
Journal: Annals of Oncology (2022)
Human kidney-derived hematopoietic stem cells can support long-term multilineage hematopoiesis
Authors: Steicy Sobrino, Chrystelle Abdo, Bénédicte Neven, Adeline Denis, Nathalie Gouge-Biebuyck, Emmanuel Clave, Soëli Charbonnier, Tifanie Blein, Camille Kergaravat, Marion Alcantara, Patrick Villarese, Romain Berthaud, Laurène Dehoux, Souha Albinni, Esma Karkeni, Chantal Lagresle-Peyrou, Marina Cavazzana, Rémi Salomon, Isabelle André, Antoine Toubert, Vahid Asnafi, Capucine Picard, Stéphane Blanche, Elizabeth Macintyre, Olivia Boyer, Emmanuelle Six, Julien Zuber
Journal: Kidney International (2022)
488P Phase I trial of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in follicular lymphoma (FL), small cell lung cancer (SCLC) and castration-resistant prostate cancer (CRPC)
Authors: M. Schweizer, K.D. Penkov, A.W. Tolcher, A.D. Choudhury, V. Doronin, R. Aljumaily, E. Calvo, R.C. Frank, J.T. Hamm, V. Moreno Garcia, V. Vorobyev, S. Billotte, T. Bowler, J. Chen, T. Lin, L. Liu, A. Maity, S. Sharma, M.L. Johnson
Journal: Annals of Oncology (2022)
384P Concordance of genomic alterations in tumour tissue and ctDNA in patients with colorectal cancer referred for early phase trials
Authors: N.C. Ramchander, N. Billy Graham Mariam, S. Rack, K. Shohdy, A. Ortega Franco, F. Thistlethwaite, D.M. Graham, L. Carter, S. Dransfield, A. Henshaw, E. Darlington, D. Rothwell, G.J. Burghel, C. Dive, M.G. Krebs, N. Cook
Journal: Annals of Oncology (2022)
753P Targeting solid tumors with IMA402, a next-generation bispecific T cell engaging receptor against PRAME
Authors: S. Missel, S. Bunk, M. Hofmann, G. Pszolla, M. Hutt, F. Schwoebel, F. Unverdorben, C. Wagner, M. Jaworski, H. Schuster, F. Schwoerer, C. Schraeder, O. Schoor, T. Weinschenk, D. Maurer, C. Reinhardt
Journal: Annals of Oncology (2022)
789O Neoadjuvant cemiplimab in patients (pts) with stage II–IV (M0) cutaneous squamous cell carcinoma (CSCC): Primary analysis of a phase II study
Authors: N. Gross, D.M. Miller, N. Khushanlani, V. Divi, E.S. Ruiz, E.J. Lipson, F. Meier, Y.B. Su, P.L. Swiecicki, J.L. Atlas, J.L. Geiger, A. Hauschild, J.H. Choe, B.G.M. Hughes, S-Y. Yoo, K. Fenech, M.D. Mathias, H. Han, M.G. Fury, D. Rischin
Journal: Annals of Oncology (2022)